Clearside Biomedical, Inc. (NASDAQ:CLSD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
In connection with the entry by Clearside Biomedical, Inc. (the “Company”) into the REGENXBIO Option and License Agreement (as defined below), on August 29, 2019, the Company entered in a Consent and Second Amendment to Second Amended and Restated Loan and Security Agreement (the “Second Amendment”), by and among Silicon Valley Bank, ELM 2016-1 Trust and ELM 2018-2 Trust (collectively, the “Lenders”). to the Second Amendment, among other things, the Lenders consented to the Company’s entry into the REGENXBIO Option and License Agreement and the Company granted the Lenders a security interest in the Company’s intellectual property.
The foregoing summary description of certain terms of the Second Amendment is not complete and is qualified in its entirety by reference to the text of the Second Amendment, which the Company expects to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.
Item 7.01 Regulation FD Disclosure.
On September 4, 2019, the Company announced that it entered into an option and license agreement with REGENXBIO, Inc. (the “REGENXBIO Option and License Agreement”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Clearside Biomedical, Inc. Exhibit
EX-99.1 2 clsd-ex991_6.htm EX-99.1 clsd-ex991_6.htm Exhibit 99.1 REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 • REGENXBIO expands RGX-314 gene therapy program to evaluate Clearside’s proprietary,…
To view the full exhibit click here
About Clearside Biomedical, Inc. (NASDAQ:CLSD)
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.
